Search

The engineered immune cells secrete powerful drugs as a layer of defense.

… Monday, August 13, 2018 Summary A technological advance may make a cell-based immunotherapy more effective against hard-to-treat cancers. Scientists at Memorial Sloan Kettering announced today that they have built a new model of genetically engineered immune cells, ones with powerful “armor” that may

MSK’s Supportive Care Service aims to improve quality of life for all people with cancer.

… Thursday, February 15, 2018 Summary People with cancer and their families can benefit from supportive care services regardless of their type or stage of disease. The doctors, nurses, and other staff at Memorial Sloan Kettering are focused on all aspects of cancer care. This means that in addition to

Degrees were presented and awards were given at the 39th annual ceremony, held on May 30.

… Friday, June 1, 2018 GSK group photo Leadership from MSK (seated) with PhD recipients from GSK and Weill Cornell at the May 30 ceremony Neuroscientist Cori Bargmann Neuroscientist Cori Bargmann, recipient of the Memorial Sloan Kettering Medal for Outstanding Contributions to Biomedical Science MSK President

Even the most common cancers have aspects that are not fully grasped by the public.

… Saturday, December 15, 2018 Summary The five most common cancers in the United States are skin cancer , lung cancer , breast cancer , prostate cancer , and colorectal cancer . MSK specialists in each of these diseases say there are aspects of them that many people overlook or do not fully appreciate.

Memorial Sloan Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer.

… Wednesday, October 17, 2012 Summary Memorial Sloan Kettering’s new research complex contains more than 100 laboratories, nearly doubling the space we dedicate to research to better understand and treat cancer. Construction on the Mortimer B. Zuckerman Research Center – named in recognition of the $100

The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma. The drug, also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering.

… Tuesday, January 5, 2021 The US Food and Drug Administration (FDA) has approved the drug naxitamab (Danyelza) for the treatment of patients with high-risk neuroblastoma.  The drug , also known as humanized 3F8, was developed by researchers at MSK Kids, the pediatric cancer program at Memorial Sloan Kettering

美国食品药品监督管理局 (FDA) 已批准将 naxitamab (Danyelza) 用于高危神经母细胞瘤患者的治疗。 该药物也称为人源化 3F8，由纪念斯隆凯特琳儿科癌症项目 MSK 斯隆儿科项目的研究人员开发。

… Tuesday, January 5, 2021 美国食品药品监督管理局 (FDA) 已批准将 naxitamab (Danyelza) 用于高危神经母细胞瘤患者的治疗。 该药物 也被称为人源化 3F8，由纪念斯隆凯特琳儿科癌症项目 MSK 斯隆儿科项目的研究人员开发。 Naxitamab 的临床试验由儿科肿瘤医生 Brian Kushner 和 MSK 斯隆儿科项目的神经母细胞瘤团队主导开展。 如今美国和全球的患者将更容易获得这种治疗。 神经母细胞瘤 是一种罕见的神经组织癌症，通常源于腹部。 其主要影响幼儿群体。 尽管过去这种疾病在几乎所有的高危病例中都是致命的，但在过去的二十年中，其前景得到了相当大的改善

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder cancer (NMIBC).

… Monday, April 29, 2024 MSK Clinical Trials for Patients with BCG-Naïve, BCG-Exposed, and BCG-Unresponsive Bladder Cancer Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) are conducting a range of clinical trials of promising new treatments for patients with non-muscle invasive bladder

Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients.

… Friday, October 25, 2013 Summary Memorial Sloan Kettering is joining with two other academic institutions in a pioneering collaboration to speed early-stage drug discoveries into therapies for patients. Despite tremendous advances in medical research in recent decades, the number of new treatments that

Structural biologist Stephen Long talks about how his team used x-ray crystallography to discover the structure of an ion channel called K2P1.

… Wednesday, February 8, 2012 Summary Structural biologist Stephen Long talks about how his team used x-ray crystallography to discover the structure of an ion channel called K2P1. For the first time, Memorial Sloan Kettering investigators have revealed the three-dimensional shape of a protein called K2P1